Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

309
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
309
Mechanistic Models: Compartment Models in Individual and Population Analysis01:23

Mechanistic Models: Compartment Models in Individual and Population Analysis

68
Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least...
68
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

101
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
101
Statistical Inference Techniques in Hypothesis Testing: Parametric Versus Nonparametric Data01:16

Statistical Inference Techniques in Hypothesis Testing: Parametric Versus Nonparametric Data

166
Statistical inference techniques, paramount in hypothesis testing, differentiate into two broad categories: parametric and nonparametric statistics.
Parametric statistics, as the name suggests, assumes that data follow a specific distribution, often a normal distribution. This assumption enables robust hypothesis testing and estimation. Parametric methods, like the Student's t-test or Goodness-of-fit test, are frequently employed in biostatistics due to their robustness. For instance,...
166
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

187
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
187
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

200
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
200

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Statistical analysis plan considerations for autologous cell and cell-based gene therapy clinical trials.

Journal of biopharmaceutical statistics·2026
Same author

Overview of dose-finding designs and trials in cell and gene therapies.

Journal of biopharmaceutical statistics·2026
Same author

The Jury Remains Out: The Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC) Study Highlights the Need for Stringent Trials Investigating the Efficacy of Surgical Intervention.

Annals of surgical oncology·2026
Same author

Indium-Based Octahedra Coordinating Pb-I Termini for Stable Perovskites.

Nature communications·2026
Same author

Trajectories of cognitive performance in the six months after hospitalization with COVID-19 among community-dwelling older adults.

The journals of gerontology. Series A, Biological sciences and medical sciences·2026
Same author

Color2Struct: efficient and accurate deep-learning inverse design of structural color with controllable inference.

Optics express·2026

Related Experiment Video

Updated: Jul 29, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.5K

Adaptively leveraging external data with robust meta-analytical-predictive prior using empirical Bayes.

Hongtao Zhang1, Yueqi Shen2, Judy Li3

  • 1Biostatistics and Research Decision Sciences, Merck & Co., Inc., North Wales, Pennsylvania, USA.

Pharmaceutical Statistics
|May 23, 2023
PubMed
Summary

We introduce a new empirical Bayes robust meta-analytical-predictive (EB-rMAP) prior. This method adaptively uses external data, overcoming challenges in study design for robust statistical analysis.

Keywords:
empirical Bayesmeta-analytical-predictive priorprior-data conflictrobustness

More Related Videos

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.2K
A Novel Bayesian Change-point Algorithm for Genome-wide Analysis of Diverse ChIPseq Data Types
12:39

A Novel Bayesian Change-point Algorithm for Genome-wide Analysis of Diverse ChIPseq Data Types

Published on: December 10, 2012

11.4K

Related Experiment Videos

Last Updated: Jul 29, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.5K
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.2K
A Novel Bayesian Change-point Algorithm for Genome-wide Analysis of Diverse ChIPseq Data Types
12:39

A Novel Bayesian Change-point Algorithm for Genome-wide Analysis of Diverse ChIPseq Data Types

Published on: December 10, 2012

11.4K

Area of Science:

  • Biostatistics
  • Clinical Trial Design
  • Statistical Modeling

Background:

  • Robust meta-analytical-predictive (rMAP) priors effectively utilize external data but require pre-specifying mixture coefficients, posing challenges during study design.
  • The selection of an appropriate mixture coefficient is critical for balancing prior-data conflict, yet it is difficult to determine prospectively.

Purpose of the Study:

  • To propose a novel empirical Bayes robust MAP (EB-rMAP) prior for adaptively leveraging external or historical data in statistical analyses.
  • To address the practical limitations of pre-specifying mixture coefficients in rMAP priors at the study design stage.
  • To develop a flexible and computationally efficient framework applicable to various endpoint types.

Main Methods:

  • The EB-rMAP prior framework is developed, building upon Box's prior predictive p-value.
  • A tuning parameter is incorporated to balance model parsimony and flexibility.
  • The framework is designed for application to binomial, normal, and time-to-event data endpoints.
  • Computational efficiency is a key feature of the EB-rMAP prior implementation.

Main Results:

  • Simulation studies confirm that the EB-rMAP prior demonstrates robustness when encountering prior-data conflict.
  • The proposed method effectively preserves statistical power in the presence of conflicting data.
  • The EB-rMAP prior was successfully applied to a dataset encompassing 10 oncology clinical trials, including a prospective study.

Conclusions:

  • The EB-rMAP prior offers a robust and adaptive approach to incorporating external data in statistical modeling.
  • This novel framework simplifies study design by eliminating the need for pre-specified mixture coefficients.
  • The EB-rMAP prior provides a flexible, efficient, and powerful tool for biostatistical applications in clinical research.